Performance of the architect EBV antibody panel for determination of Epstein-Barr virus infection stage in immunocompetent adolescents and young adults with clinical suspicion of infectious mononucleosis

Clinical and Vaccine Immunology

Volumn 21, Issue 6, 2014, Pages 817-823

  Guerrero Ramos, Alvaro ^a   Patel, Mauli ^a   Kadakia, Kinjal ^a   Haque, Tanzina ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; VIRUS CAPSID ANTIGEN; CAPSID PROTEIN; EBV-ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARCHITECT EPSTEIN BARR VIRUS ANTIBODY PANEL; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CROSS REACTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOCOMPETENCE; MAJOR CLINICAL STUDY; MALE; MONONUCLEOSIS; PILOT STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEQUENTIAL ANALYSIS; YOUNG ADULT; BLOOD; CYTOMEGALOVIRUS INFECTIONS; ECONOMICS; IMMUNOLOGY; INFECTIOUS MONONUCLEOSIS; LUMINESCENCE; RETROSPECTIVE STUDY; SEROLOGY; VIRUS CAPSID;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID; CAPSID PROTEINS; COST-BENEFIT ANALYSIS; CROSS REACTIONS; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFECTIOUS MONONUCLEOSIS; LUMINESCENT MEASUREMENTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; YOUNG ADULT;

EID: 84901596041     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00754-13     Document Type: Article

References (34)

1. Sprunt TP, Evans FA. 1920. Mononucleosis leukocytosis in reaction to acute infections (infectious mononucleosis). Bull. Johns Hopkins Hosp. 31:410-417.
2. Hallee TJ, Evans AS, Niederman JC, Brooks CM, Voegtly H. 1974. Infectious mononucleosis at the United States military academy. A prospective study of a single class over four years. Yale J. Biol. Med. 47:182-195.
3. Luzuriaga K, Sullivan JL. 2010. Infectious mononucleosis. N. Engl. J. Med. 362:1993-2000. http://dx.doi.org/10.1056/NEJMcp1001116.
4. Hurt C, Tammaro D. 2007. Diagnostic evaluation of mononucleosis-like illnesses. Am. J. Med. 120:911.e1-911.e8. http://dx.doi.org/10.1016/j.amjmed. 2007.08.018.
5. Hess RD. 2004. Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J. Clin. Microbiol. 42:3381-3387. http://dx.doi.org/10.1128/JCM.42.8.3381-3387.2004. (Pubitemid 39045655)
6. Tselis A, Merline JR, Storch GA. 2006. Epstein-Barr virus diseaseserologic and virologic diagnosis, p 126-146. In Tselis A, Jenson HB (ed), Epstein-Barr virus, 1st ed. Taylor & Francis Group, New York, NY.
7. Gärtner BC, Hess RD, Bandt D, Kruse A, Rethwilm A, Roemer K, Mueller-Lantzsch N. 2003. Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin. Diagn. Lab. Immunol. 10:78-82. http://dx.doi.org/10.1128/CDLI.10. 1.78-82.2003. (Pubitemid 36133833)
8. Middeldorp JM, Herbrink P. 1988. Epstein-Barr virus specific marker molecules for early diagnosis of infectious mononucleosis. J. Virol. Methods 21:133-146. http://dx.doi.org/10.1016/0166-0934(88)90060-2.
9. Kieff E, Rickinson AB. 2007. Epstein-Barr virus, p 2655-2700. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
10. Bauer G. 2001. Simplicity through complexity: immunoblot with recombinant antigens as new gold standard in Epstein-Barr virus serology. Clin. Lab. 47:223-230. (Pubitemid 32492869)
11. Gärtner BC, Fischinger JM, Roemer K, Mak M, Fleurent B, Mueller-Lanztsch N. 2001. Evaluation of a recombinant line blot for diagnosis of Epstein-Barr virus compared with ELISA, using immunofluorescence as reference method. J. Virol. Methods 93:89-96. http://dx.doi.org/10.1016/S0166-0934(00) 00301-3. (Pubitemid 32322518)
12. Crowley A, Connell J, Schaffer K, Hall W, Hassan J. 2012. Is there diagnostic value in detection of immunoglobulin G antibodies to the Epstein-Barr virus early antigen? Biores. Open Access 1:291-295. http://dx.doi.org/10.1089/ biores.2012.0274.
13. Weeks I, Kricka LJ, Wild D. 2013. Signal generation and detection systems (excluding homogeneous assays), p 267-285. In Wild D, John R, Sheehan C, Binder S, He J. (ed), The immunoassay handbook, 4th ed. Elsevier Ltd., Oxford, United Kingdom.
14. Green M, Michaels MG. 2013. Epstein-Barr virus infection and post-transplant lymphoproliferative disorder. Am. J. Transplant. 13:41-54. http://dx.doi.org/10.1111/ajt.12004.
15. Health Protection Agency. 2012. UK standards for microbiology investigations: Epstein-Barr virus serology. Health Protection Agency, London, United Kingdom. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1317131313375.
16. th Mikrogen spring symposium.
17. Henle G, Henle W. 1979. The virus as the etiologic agent of infectious mononucleosis, p 279-320. In Epstein MA, Achong BG (ed), The Epstein-Barr virus, 1st ed. Springer-Verlag, Berlin, Germany.
18. Obel N, Høier-Madsen M, Kangro H. 1996. Serological and clinical findings in patients with serological evidence of reactivated Epstein-Barr virus infection. APMIS 104:424-428. http://dx.doi.org/10.1111/j.1699-0463.1996. tb00737.x. (Pubitemid 26264357)
19. Henle W, Henle G, Andersson J, Ernberg I, Klein G, Horwitz CA, Marklung G, Rymo L, Wellinder C, Straus SE. 1987. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc. Natl. Acad. Sci. U. S. A. 84:570-574. http://dx.doi.org/10.1073/pnas.84.2.570. (Pubitemid 17006237)
20. Berth M, Bosmans E. 2010. Comparison of three automated immunoassay methods for the determination of Epstein-Barr virus-specific immunoglobulin M. Clin. Vaccine Immunol. 17:559-563. http://dx.doi.org/10.1128/CVI.00372-09.
21. Wiedbrauk DL, Bassin S. 1993. Evaluation of five enzyme immunoassays for detection of immunoglobulin M antibodies to Epstein-Barr virus viral capsid antigens. J. Clin. Microbiol. 1993. 31:1339-1341. (Pubitemid 23129474)
22. Weber B, Brunner M, Preiser W, Doerr HW. 1996. Evaluation of 11 enzyme immunoassays for the detection of immunoglobulin M antibodies to Epstein-Barr virus. J. Virol. Methods 57:87-93. http://dx.doi.org/10.1016/0166-0934(95)01971- 5. (Pubitemid 26093967)
23. Robertson P, Beynon S, Whybin R, Brennan C, Vollmer-Conna U, Hickie I, Lloyd A. 2003. Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection. J. Med. Virol. 70:617-623. http://dx.doi.org/10.1002/jmv.10439. (Pubitemid 36734728)
24. Evans AS. 1978. Infectious mononucleosis and related syndromes. Am. J. Med. Sci. 276:325-339. http://dx.doi.org/10.1097/00000441-197811000-00010. (Pubitemid 9100092)
25. de Ory F, Guisasola ME, Sanz JC, García-Bermejo I. 2011. Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections. Clin. Vaccine Immunol. 18:444-448. http://dx.doi.org/10. 1128/CVI.00486-10.
26. Aalto SM, Linnavuori K, Peltola H, Vuori E, Weissbrich B, Schubert J, Hedman L, Hedman K. 1998. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J. Med. Virol. 56:186-191. http://dx.doi.org/10.1002/(SICI)1096-9071(199811)〈186::AID-JMV2〉3.0. CO;2-3.
27. Klemola E, Von Essen R, Henle G, Henle W. 1970. Infectious mononucleosis-like disease with negative heterophil agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies. J. Infect. Dis. 121:608-614.
28. Rosenberg ES, Caliendo AM, Walker BD. 1999. Acute HIV infection among patients tested for mononucleosis. N. Engl. J. Med. 340:969. http://dx.doi.org/10.1056/NEJM199903253401217. (Pubitemid 29141066)
29. Naito T, Kudo N, Inui A, Matsumoto N, Takeda N, Isonuma H, Dambara T, Hayashida Y. 2006. Causes of infectious mononucleosis-like syndrome in adult patients. Intern. Med. 45:833-834. http://dx.doi.org/10.2169/internalmedicine. 45.1725. (Pubitemid 44194352)
30. Post JJ, Chan MK, Whybin LR, Shi Q, Rawlinson WD, Cunningham P, Robertson PW. 2011. Positive Epstein-Barr virus and cytomegalovirus IgM assays in primary HIV infection. J. Med. Virol. 83:1406-1409. http://dx.doi.org/10.1002/jmv. 22109.
31. Jones JW, Pether JV, Frost RW. 1994. Human parvovirus B19. Hard to differentiate from infectious mononucleosis. BMJ 308:595. (Pubitemid 24084317)
32. Costa E, Tormo N, Clari MA, Bravo D, Muñoz-Cobo B, Navarro D. 2009. Performance of the Epstein-Barr virus and herpes simplex virus immunoglobulin M assays on the Liaison platform with sera from patients displaying acute parvovirus B19 infection. Clin. Vaccine Immunol. 16:1247-1248. http://dx.doi.org/10.1128/CVI.00142-09.
33. Berth M, Bosmans E. 2009. Acute parvovirus B19 infection frequently causes false-positive results in Epstein-Barr virus- and herpes simplex virus-specific immunoglobulin M determinations done on the Liaison platform. Clin. Vaccine Immunol. 16:372-375. http://dx.doi.org/10.1128/CVI.00380-08.
34. De Paschale M, Clerici P. 2012. Serological diagnosis of Epstein-Barr virus infection: problems and solutions. World J. Virol. 1:31-43. http://dx.doi.org/10.5501/wjv.v1.i1.31.